-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Immunovant, Raises Price Target to $44

Benzinga·02/09/2026 14:44:36
Listen to the news
Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $41 to $44.